OSMOVIST 190 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Osmovist 190, and when can generic versions of Osmovist 190 launch?
Osmovist 190 is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in OSMOVIST 190 is iotrolan. Additional details are available on the iotrolan profile page.
Summary for OSMOVIST 190
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 38 |
Patent Applications: | 1,110 |
Formulation / Manufacturing: | see details |
DailyMed Link: | OSMOVIST 190 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for OSMOVIST 190
US Patents and Regulatory Information for OSMOVIST 190
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Hlthcare | OSMOVIST 190 | iotrolan | INJECTABLE;INTRATHECAL | 019580-001 | Dec 7, 1989 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |